Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .
Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery
Objectives This study aim ed to ( a ) investigate whether atorvastatin reload protects against acute heart failure ( AHF ) in patients with stable coronary artery disease ( CAD ) undergoing noncardiac emergency surgery and decreases the incidence of major adverse cardiac events ( MACE ) during hospitalization and ( b ) eluci date its possible mechanism of action . Material s and methods In total , 500 patients with stable CAD before noncardiac emergency surgery were r and omized either to the atorvastatin reload or to the  placebo group . All patients received atorvastatin treatment postoperatively . The primary end point was the incidence of AHF during hospitalization , and the secondary end point was the incidence of MACE during hospitalization . Preoperative and 72 h postoperative changes in high-sensitivity C-reactive protein and interleukin-6 levels were compared between the two groups . Results AHF during hospitalization occurred in 5.2 % of patients in the atorvastatin reload group and 11.2 % in the placebo group ( P=0.0225 ) . MACE during hospitalization occurred in 2.4 % of patients in the atorvastatin reload group and 8.0 % in the placebo group ( P=0.0088 ) . According to multivariable analysis , atorvastatin reload conferred a 50 % reduction in the risk of AHF during hospitalization ( odds ratio , 0.50 ; 95 % confidence interval , 0.2–0.8 ; P=0.005 ) . The median decrease in the high-sensitivity C-reactive protein and interleukin-6 levels was significantly greater in the atorvastatin reload group ( P<0.001 ) . Conclusion Atorvastatin reload may improve the clinical outcome of patients with stable CAD undergoing noncardiac emergency surgery by decreasing the incidence of AHF and MACE during hospitalization . The mechanism of this protective effect may involve inhibition of inflammation
Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .